Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, discusses the future of acute myeloid leukemia (AML) treatment, highlighting the approval of oral azacitidine as a maintenance therapy for patients undergoing induction chemotherapy who are not eligible for curative therapy as a result of the Phase III QUAZAR AML-001 trial (NCT01757535). Dr Lee also discusses how future research will focus on developing oral hypomethylating agents to be used in combination with oral venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть